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Polypyrimidine tract binding protein (PTB in humans) has been extensively characterized as an
important splicing factor, and has additional functions in 30 end processing and translation. ROD1
is a PTB paralog containing four RRM (RNA recognition motif) domains. Here, we discover a function
of ROD1 in nonsense-mediated mRNA decay (NMD). We show that ROD1 and the core NMD factor
UPF1 interact and co-regulate an extensive number of target genes. Using a reporter system, we
demonstrate that ROD1, similarly to UPF1 and UPF2, is required for the destabilization of a known
NMD substrate. Finally, we show through RIP-seq that ROD1 and UPF1 associate with a signiﬁcant
number of common transcripts.
Structured summary of protein interactions:
ROD1 physically interacts with TMED10, RNP1, PCD6, LOC493753, RBM39, BCL7C, GST-PI, AP-3, RAE1,
ASH2L2, SF3B10, SDP3, CDC23, ARL10C, CAF1B, CEP55, EXPORTIN 1, NCOR1, LENG1, SNAP29, RCBTB1,
RPS10, NUP155, DYNLL2, LSF, HSPC137, TNRC6C, XPO5, TMPO, SRP19, SRI, UPF2, TRF2, SSRP1, HOXB9,
C11ORF73, TAF15,WDR48, SMARCA5, CUL-2, THOC2, SEC16A, CAD, LSM2, U11/U12 snRNP, TUBA, NEZ-
HA, TRANSPORTIN 2, CGI-135, RER1, snRP E, PRPF19, TRANSPORTIN, IER3ip1, DGCR14, RPS19BP1,
TOPBP1, YIP1, CPSF6, ASF1, RBM9, ARCN1, U4/U6 snRNP, CUGbp2, WDR41, p53, DNAJC9, DAZap1,
TDP43,MYL6, HEY1, RAB8B, BET1, COFILIN1,MYO12A, VAT1, PRA1,MAP7D2,MAZ, PCD7, DNAJ, GNL3L,
BCAS2, NUP50, RGSip1, TRIM33B, HMG-1, RAB10, ANNEXIN A2, YKT6, TRANSFERRIN, TIM44, CTP syn-
thase, CDC42, PPIL1, HOXA9B, GCN1, hnRNP A1, LDH-B, TRAP25,mtSSB,MED8, TIA1, HMMR, B99, H1d,
IMPORTIN 5, HOX7, ZMAT5, RPR1A, MARCKS, NACA, PRMT1, HOXC9, KIAA1741, HSP90AA1, LSM14,
COL1A1, PRC1, CDK2, TRX-1, CSE1, COX5B, ARL1, SEPT9, BCR/ABL, CLIP-ap1, ALY, BACH1, TRIP230,
DES, GFAP, APC10, MARK2, FIP1l1, RPL38, HOXC8, GATAd2A, HSPC128, TUBB, RPL11, FAM83D, UPF1,
ZFP768, RPL35A, RPL30, RAB1A, BTEbp4, RNA Pol II, SEC24B, RAN, RAC3, RPS28, RPS27, snRP A,
SNF5/INI1, C1ORF35, RPS7, RPS4X, RAMA1, RPS14, TUBA6, FAM128B, T-PLASTIN, FLYWCH, MYH10,
ARP1, U2AF, SERPINE1, NEFM, KIAA1826, Ki-67 and RPS11 by anti bait coimmunoprecipitation (View
interaction)
ROD1 physically interacts with LOC100288473, PTBP1, LOC100291593, RRP36, PCMT1, BBS9, FAM83H,
ARHGEF17, VIPAR, LOC100132738, PTBP2, SACS, KBTBD5, GPR98, hnRNP F, OTUD4, CAMSAP1L1,
C16ORF48, FAM64A, SCN3A, IQGAP3, ZMAT5, TEX15, NOL8, RBM4, snRNP48, TMEM33, UNC45A, OGT,
DIAPH3, CDK17, LARS, FAM83D, TMTC2, HSPA1A, PCM1, CSNK1A1, PHF5A, CCDC77, PLECTIN, SETX,
HSPB1, HuR, NARF, MYH2, HSP90AA1, HLTF, GSK3b, CDC42, MAGOH, TRIM21, UPF1, RBMS1, ERI1,
CROCC, CSNK1D, CTNNA1, AIMP2, VPS33B, FLII, CTNNB1, eIF4G2, APC, TCF20, CYCLIN T1, HIRA, BACH1,
XRCC6, HMMR, RPL9, HSD17B4, MAP2, hnRNP H1, GRIA4, FRG1, HistH1e, MSH6, CELF2, CELF1,
MYBbp1A, CLASP2, STIP1, GIPC1, SF3a1, CSNK1E, CDC14A, PPIH, RBM14, DYNLL2, RALY, PUF60,chemical Societies. Published by Elsevier B.V. All rights reserved.
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1102 T.F. Brazão et al. / FEBS Letters 586 (2012) 1101–1110TRIM33, SF3b1, TARDBP, PAPD7, SF3b2, LRRFIP2, SUPT16H, FAM110B, hnRNP Ul1, KIAA1543, AXIN1,
RNP1, HERC1, BANF1, XRCC5, XPC, FYTTD1, PDCD7, TAF15, YWHAH, RB1CC1, MATR3, SRRM1, SFRS14,
LAGE3, XIRP1, ARHGEF2, PRPF3, PUM1 and IQCB1 by anti bait coimmunoprecipitation (View
interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction washed, eluted, trypsinized and analysed by mass spectrometry.Post-transcriptional mechanisms play an important role in the
regulation of gene expression through a multitude of RNA-binding
proteins. These participate in diverse steps of post-transcriptional
regulation to ensure proper transcript maturation, nuclear export
and translation. hnRNPs comprise a family of around 20multi-func-
tional RNA-binding proteins which shuttle between the nucleus
and cytoplasm [1,2] and most have paralogs and/or splice variants.
In some cases these are shown to be functionally distinct from each
other, adding to the multi-functionality of these proteins [3]. Sev-
eral hnRNPs are implicated in several diseases such as cancer [4–
7], Alzheimer [8], spinal muscular atrophy (SMA) [1] or familial
amyotrophic lateral sclerosis (FALS) [9]. One of the best studied
hnRNPs is PTB (polypyrimidine tract binding protein, or hnRNP I),
an essential RNA-binding protein with roles in RNA splicing, 30
end processing and translation [10–13]. PTB has two paralogs, nPTB
(neural PTB) and ROD1 (regulator of differentiation 1; PTBP3), with
a similar protein architecture and containing four RNA recognition
motifs (RRMs). In adults, nPTB is expressed in neurons [14] while
ROD1 is expressed mainly in hematopoietic cells [15]. PTB, nPTB
and ROD1 display auto and cross-regulation: PTB regulates its
own transcript by promoting the skipping of exon 11, which gener-
ates a premature termination codon (PTC) and subsequent mRNA
degradation by nonsense-mediatedmRNA decay (NMD) [16], while
the knock-down of PTB up-regulates nPTB and a double knock-
down of PTB and nPTB up-regulates ROD1 [17]. Codon usage pro-
vides an additional level of regulation: nPTB expression was shown
to be limited by suboptimal codon content and the same effect was
observed for ROD1 ([18]; Chris Smith, unpublished data).
In contrast to the extensive studies of the cellular functions of
PTB, ROD1 has not been thoroughly characterized. A functional
ROD1 homolog in Saccharomyces cerevisae named Nrd1 has been
implicated in the RNA degradation of cryptic unstable transcripts
(CUTs) [19,20] and Nrd1 was found to regulate the differentiation
of ﬁssion yeast in response to metabolic cues [21]. To elucidate
the cellular functions of ROD1 in mammalian cells, we character-
ized ROD1 protein complexes by mass spectrometry in HEK293
(human embryonic kidney) cells. We identify a role for ROD1 in
nonsense-mediated mRNA decay (NMD) and show that ROD1 and
the essential NMD factor UPF1 share many endogenous targets,
which we validate as bona-ﬁde NMD targets. Finally, we analyse
both ROD1 and UPF1-bound RNAs by RIP-seq (RNA immunoprecip-
itation-sequencing). ROD1-bound transcripts overlap signiﬁcantly
with UPF1-bound ones; interestingly, ROD1 has a bias for binding
UPF1-repressed transcripts. Together, our data uncovers a new
function of ROD1 in nonsense-mediated mRNA decay.
2. Results
2.1. ROD1 interacts with protein factors involved in nonsense-
mediated mRNA decay
In order to identify ROD1 interacting proteins we immunopre-
cipitated ROD1 protein complexes from both nuclear and cytoplas-
mic extracts of HEK293 (human embryonic kidney). We used an
antibody against human ROD1 cross-linked to protein G magnetic
beads to immunoprecipitate ROD1 complexes, which were thenThe immunoprecipitations were performed in the presence of ben-
zonase, in order to avoid pulling down factors through RNA–pro-
tein interactions. We used Mascot scores to rank interactors and
ﬁltered out scores below 40. ROD1 was present in both sets of re-
sults (nuclear and cytoplasmic) with high Mascot scores (663 and
500, respectively), indicating that both immunoprecipitations were
successful (Supplementary Tables 1 and 2). We performed a gene
ontology analysis and found that factors related to transport,
RNA trafﬁcking and RNA modiﬁcation were best represented
among all ROD1 interactors (Fig. 1A). Included in the RNA trafﬁck-
ing proteins, the core NMD factors UPF1 and UPF2 had particularly
high Mascot scores as nuclear interactors suggesting that they
strongly bind nuclear or nucleus-associated ROD1; furthermore,
UPF1 was also present as a cytoplasmic interactor. UPF1 and
UPF2 function in NMD, a surveillance mechanism which degrades
transcripts containing premature termination codons (PTCs) [22];
this prevents the synthesis of truncated proteins which may cause
dominant-negative effects. For many endogenous targets, RNA
degradation through NMD relies on the EJC (exon junction com-
plex), a protein complex which assembles during splicing and
marks intron positions throughout the transcript’s life [23,24].
Interestingly, two EJC components were also present in the mass
spectrometry results: ALY/REF is implicated in RNA export and
was present as a nuclear interacting protein [25], while MAGOH,
a core EJC factor required for recruitment of other EJC factors
[26,27], was present as a cytoplasmic interacting protein (Supple-
mentary Tables 1 and 2). In order to conﬁrm the nuclear ROD1
interactions with UPF1, UPF2 and ALY/REF we performed indepen-
dent immunoprecipitations in the presence of benzonase followed
by Western blot (Fig. 1B). We conclude that ROD1 interacts with
UPF1, UPF2 and ALY/REF independently of nucleic acids.
2.2. ROD1 is necessary for destabilizing a reporter b-globin PTC-
containing transcript
Given the interactions with the NMD factors UPF1 and UPF2, as
well as with the EJC factor ALY/REF, we next addressed the possi-
bility of ROD1 involvement in NMD. To study this, we transiently
transfected HEK293 cells with a reporter b-globin construct con-
taining a NMD-sensitive nonsense mutation in codon 39 (NS39 –
[28]), or the wild-type construct as control (wt), and performed
lentiviral-mediated RNAi against ROD1, UPF2, UPF1 or control
(Fig. 2A and B). Reporter mRNA levels were quantiﬁed by RT-PCR
(Fig. 2C). The NS39 transcript levels were 30% of the wt in the RNAi
control, conﬁrming degradation of the PTC-carrying transcript.
NS39 levels, measured as a fraction of the wt counterpart, in-
creased to 46%, 78% and 73% upon knock-down of UPF1, UPF2
and ROD1, respectively (Fig. 2C). We obtained similar results
through analysis of reporter transcript levels by northern blot
(Supplementary Fig. 1). We observed a slight reduction of UPF1
protein levels upon ROD1 knock-down; however, this reduction
is not signiﬁcant compared to the reduction of UPF1 protein levels
upon UPF1 knock-down (Fig. 2B) and therefore cannot account for
the increased stabilization of the NS39 transcript upon RNAi
against ROD1 (Fig. 2C). These results indicate that ROD1, similarly
to UPF2 and UPF1, is required for the NMD-dependent degradation
of the NS39 transcript in HEK293 cells.
Fig. 1. A – Gene ontology analysis of nuclear and cytoplasmic ROD1 interactors; the top 10 functional categories enriched among ROD1 interactors are shown. B – Western
blot showing co-precipitation of UPF2, UPF1 and ALY/REF following ROD1 immunoprecipitation from nuclear HEK293 extracts.
T.F. Brazão et al. / FEBS Letters 586 (2012) 1101–1110 11032.3. ROD1 and UPF1 regulate common potential nonsense-mediated
mRNA decay targets
The interactions of ROD1 with UPF2, UPF1 and ALY and the sta-
bilization of a b-globin transcript containing a nonsense mutation
upon ROD1 knock-down suggest that ROD1 may regulate physio-
logical NMD targets in HEK293 cells. To verify this, we performed
triplicate RNAi experiments targeting ROD1 or UPF1 and isolatedtotal RNA, which was hybridized to a human exon array platform
interrogating over one million exon clusters within the human
genome. A total of 1158 (6.9% of the total number of genes in the
array) and 4027 (24.0% of total) genes were mis-regulated more
than 1.5-fold upon ROD1 or UPF1 knock-down, respectively
(Fig. 3A). Signiﬁcantly, the overlap between these two sets of genes
was 435 (37.6% of ROD1 mis-regulated genes – v2 = 118.4;
P < 0.0001 and 10.8% of UPF1 mis-regulated genes – v2 = 97.3;
Fig. 2. ROD1 is required for the destabilization of a reporter b-globin transcript containing a premature termination codon in codon 39 (NS39). A – Schematic view of the
wild-type (wt) and NS39 constructs. B – Western blot showing decreased amounts of protein upon RNA interference against UPF2, UPF1 and ROD1 in HEK293 cells. C – RNA
interference against UPF1, UPF2 or ROD1 stabilize the NS39 transcript (measured as the NS39/wt ratio); mRNA levels were quantiﬁed by RT-PCR and normalized to a
transfection control.
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ROD1 knock-down, 598 (51.6%) were up-regulated; from these
598, a signiﬁcant 121 (20.2%) were also up-regulated upon UPF1
knock-down (v2 = 69.6; P < 0.0001; Fig. 3B). Conversely, from the
4027 mis-regulated genes after RNAi against UPF1, 1683 (41.8%)
were up-regulated; from these 1683, 121 (7.2%) were also up-reg-
ulated upon ROD1 knock-down (v2 = 65.1; P < 0.0001; Fig. 3B). One
hundred and twenty-one genes thus comprise the set of putative
NMD targets regulated by ROD1. ROD1 and UPF1 also shared a sig-
niﬁcant number of down-regulated targets: from 560 down-regu-
lated ROD1 targets, 174 (31.1%) were also down-regulated upon
RNAi against UPF1 (v2 = 136.8; P < 0.0001); conversely, from
2344 down-regulated UPF1 targets, 174 (7.4%) were also down-
regulated upon RNAi against ROD1 (v2 = 122.0; P < 0.0001). A com-
prehensive list of mis-regulated genes after RNAi against ROD1 or
UPF1 can be seen in Supplementary Table 3. As a complementary
analysis, we plotted the top 200 mis-regulated genes upon RNAi
against ROD1 versus RNAi against UPF1 and vice versa (Supple-
mentary Fig. 2); strikingly, for both up and down-regulated genes,
the tendency is for UPF1 and ROD1 to exert the same effect (Sup-
plementary Fig. 2). We conclude that ROD1 and UPF1 co-regulate
a large number of endogenous target genes, among which are a
group of 121 putative NMD targets.
2.4. Validation of NMD targets regulated by ROD1
We conﬁrmed the up-regulation of several of the 121 putative
NMD targets regulated by ROD1 by RT-PCR (Fig. 4A); out of 34
up-regulated genes from the exon array, 28 were conﬁrmed to be
up-regulated at least 1.5-fold by RT-PCR, representing an 82% suc-cess rate. Some of the conﬁrmed up-regulated genes have been
previously described as being NMD targets (ex. GADD45B, RIT1,
SAT1, DDIT3 and ATF3 – [29–32]). Importantly, many of these
putative NMD targets were also up-regulated upon UPF2 knock-
down (Fig. 4A), supporting the idea that these are in fact bona-ﬁde
NMD targets.
NMD substrates are degraded in a translation-dependent man-
ner, since detection of a PTC requires scanning of the transcript by
the ribosome. We therefore tested the effect of cycloheximide, a
translation inhibitor, on a set of potential NMD targets which were
conﬁrmed to be up-regulated upon RNAi against UPF1 or ROD1 by
RT-PCR. As expected for NMD substrates, the vast majority of these
transcripts (25 out of 27; 93%) were up-regulated at least 1.5-fold,
either 1, 3 or 6 h after cycloheximide treatment at a concentration
of 10 lg/ml (Fig. 4B). This result conﬁrms that translation is required
for destabilization of most of the putative NMD targets we found.
Changes in transcript levels can be due to changes in transcrip-
tion rate, changes in mRNA stability, or both. We therefore tested
whether the destabilization of potential NMD targets by ROD1 and
UPF1 was dependent on transcription; we did RNAi against ROD1
or UPF1 and followed transcript levels at different time points after
treatment with 50 lM 5,6-dichloro-1-b-D-_ribofuranosylbenzimi-
dazole (DRB), an inhibitor of transcription elongation [33]
(Fig. 4C).We tested12 transcriptswhichpassedourprevious criteria
(i.e. were conﬁrmed by RT-PCR to be up-regulated following RNAi
against ROD1 or UPF1 and following cycloheximide treatment),
and 7 clearly displayed decreased decay rate upon RNAi against
ROD1 or UPF1, compared to control RNAi (Fig. 4C). This indicates
that these transcripts are destabilized by UPF1 or ROD1 in a post-
transcriptional manner, which is consistent with NMD. Altogether,
Fig. 3. ROD1 and UPF1 co-regulate a signiﬁcant number of genes. A – Venn diagram
showing genes mis-regulated (up or down-regulated) after RNAi against ROD1 or
UPF1. B – Venn diagram showing genes up-regulated after RNAi against ROD1 or
UPF1 (potential NMD targets). Areas are proportional to the respective number of
genes.
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lated upon ROD1 or UPF1 knock-down are bona-ﬁde NMD targets.
2.5. Analysis of transcripts associated with ROD1 and UPF1 by RIP-seq
To verify whether ROD1 and/or UPF1 bind directly to NMD tar-
get transcripts we performed RNA immunoprecipitation-sequenc-
ing (RIP-seq) analysis of ROD1 and UPF1-bound RNAs from total
HEK293 extracts. The RIP-seq protocol was based on the one de-
scribed in [34] followed by sequencing in a GAIIx Illumina sequen-
cer. We set a threshold of log2FC > 2 and FDR < 0.0001 to select for
bound transcripts. According to these criteria, 1402 transcripts
were associated with UPF1, while 146 were associated with
ROD1 (Supplementary Table 4). Signiﬁcantly, from the 146
ROD1-bound transcripts, 36 (24.7%) were also associated with
UPF1 (v2 = 32.6; P < 0.0001); also signiﬁcantly, from the 1402
UPF1-bound transcripts, 36 (2.6%) were associated with ROD1
(v2 = 27.8; P < 0.0001) (Fig. 5A). This indicates that UPF1 and
ROD1, in addition to co-regulating a signiﬁcant number of genes,
associate signiﬁcantly with the same transcripts. To address the
question of whether RIP hits co-relate with the set of mis-regulated
genes from the exon arrays, we integrated the analysis of RIP-seq
with the exon array data sets. We considered only genes which
were present both in the exon arrays and in the RIP-seq results,
which amounted to 9966 genes for ROD1 and 10420 genes for
UPF1. From the 1123 up-regulated UPF1 targets (more than 1.5-
fold), 116 were UPF1 RIP hits, while from the 1934 down-regulated
UPF1 targets, 208 were UPF1 RIP hits; since these values are actu-
ally slightly lower than expected by chance (v2 = 3.85; P = 0.050
and v2 = 4.02; P = 0.045, respectively), we conclude that UPF1 doesnot always regulate transcripts to which it associates. This conclu-
sion was also valid when we set a threshold of 1,3 for mis-regu-
lated genes (data not shown). Interestingly, we did see a slight
but signiﬁcant enrichment of ROD1 RIP targets among the UPF1-re-
pressed genes: from the above-mentioned 1123 transcripts which
were up-regulated upon UPF1 knock-down, 24 were ROD1 RIP hits
(v2 = 5.22; P = 0.022). In contrast, we failed to see a signiﬁcant
association between UPF1 down-regulated genes and RIP ROD1
targets (23 ROD1 RIP hits among the 1934 down-regulated UPF1
targets – v2 = 0.375; P = 0.54). The same conclusion was taken
when we set a threshold of 1,3 for mis-regulated UPF1 targets
(data not shown). This means ROD1 tends to bind transcripts
which are destabilized, but not transcripts which are stabilized,
by UPF1. Intriguingly though, we failed to see a positive correlation
between ROD1 RIP targets and ROD1-regulated genes: from the
327 up-regulated ROD1 targets (more than 1.5-fold), there were
2 RIP hits, and from 460 down-regulated ROD1 targets there were
9 RIP hits; similarly to UPF1, these numbers are not signiﬁcant
(v2 = 1.34; P = 0.25 and v2 = 1.27; P = 0.26, respectively), from
which we conclude that ROD1 does not signiﬁcantly associate di-
rectly with its regulated transcripts. Again, we came to the same
conclusion when we set a threshold of 1,3 for mis-regulated genes
(data not shown). We veriﬁed both ROD1 and UPF1-bound tran-
scripts by RT-PCR; the RT-PCR results correlated signiﬁcantly with
the RIP-seq data (Fig. 5B). We conclude that ROD1 and UPF1 share
a signiﬁcant number of RIP targets. Furthermore, while neither
UPF1 nor ROD1 bind directly to their respective regulated tran-
scripts, ROD1 favors binding to UPF1-repressed transcripts.3. Discussion
The results presented here demonstrate an as yet unidentiﬁed
role for ROD1 (PTBP3) in NMD. The expression of ROD1 varies
widely among different cell types: it’s expressed in several embry-
onic cell types and in adult hematopoietic cells [15]. This fact raises
the question of whether NMD is differentially regulated in cell types
with different levels of ROD1 expression. This has been observed for
RNPS1, an EJC factor whose cellular levels co-relate with the efﬁ-
ciency of NMD across different cell types [35]. In addition, other
lines of evidence support a non-homogenous NMD mechanism:
Gehring et al. reported that NMD can be triggered in a UPF2-inde-
pendentmanner [36], while Chan et al. describe an UPF3b-indepen-
dent NMD pathway [37]. These studies highlight variants of the
NMD mechanism and may explain why NMD efﬁciency varies sig-
niﬁcantly across different cell types [38]. Given the expression pro-
ﬁle of ROD1 across different tissues, it is thus plausible that it could
be another factor adding to the heterogeneity of NMD.
Both nuclear (RNA splicing, RNA export) and cytoplasmic
(translation, RNA degradation) events are determinant in NMD
[23,39–43]. Given the homology with PTB, a well characterized
splicing factor, and the enrichment of splicing factors among
ROD1-binding proteins, it is possible that the role of ROD1 in
NMD is, at least partially, a reﬂection of a splicing function. Splicing
events promoted by ROD1 could eventually originate PTCs which
would render transcripts subject to degradation by NMD. However,
we failed to see an enrichment of alternatively spliced transcripts
in the set of 121 transcripts repressed by both ROD1 and UPF1,
as compared to the total set of transcripts from the exon arrays
(data not shown), thus suggesting that a possible role of ROD1 in
the regulation of splicing is not determinant in its NMD function.
In relation to this, we failed to see a positive correlation between
ROD1-associated transcripts and ROD1 alternative splicing (AS)
targets (data not shown); however, this lack of correlation may
be due to the intrinsic bias of RIP towards RNAs which are not
associated with chromatin, since chromatin is excluded during
Fig. 4. Validation of NMD targets regulated by ROD1. A – Box plot conﬁrming the up-regulation of transcripts after RNAi against ROD1, UPF1 or UPF2 by RT-PCR;  indicate
outliers. B – Cycloheximide (CHX) treatment induces up-regulation of putative NMD targets; transcripts levels were quantiﬁed by RT-PCR. C – Upon DRB treatment,
transcripts decay at a decreased rate with RNAi against ROD1 or UPF1, compared to control RNAi.
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tors of proteins involved in transport and RNA trafﬁcking might
suggest that ROD1 regulates NMD through a function in RNA trans-
port or localization, perhaps transporting NMD targets to sites of
RNA degradation. Further work is needed to decipher the mecha-
nism of ROD1 in NMD.
We do not know whether ROD1 is necessary for degradation
of all NMD targets or just a subset of them. Although our data
indicate that ROD1 represses only 121 (7.2%) out of 1683 genesrepressed by UPF1, this number might be an underestimation,
since ROD1 knock-down was incomplete. The small proportion
of ROD1-repressed genes compared to UPF1-repressed genes
can also be explained by the functional versatility of UPF1:
UPF1 is known to regulate several other processes other than
NMD, such as SMD (Staufen-mediated RNA decay), histone RNA
degradation, cell cycle progression and telomere maintenance
[44–47]. It is therefore difﬁcult to estimate the weight of NMD
on the mis-regulation of mRNA levels upon UPF1 knock-down.
Fig. 4 (continued)
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UPF1 share also a signiﬁcant number of genes which are down-
regulated after RNAi. While this could reﬂect secondary events
resulting from the shared up-regulated genes, it is possible that
ROD1 and UPF1 have an unknown mRNA stabilizing function.
4. Materials and methods
4.1. Plasmid constructs and antibodies
pcb-wt and pcb-39 were generated by inserting the PCR frag-
ments of b-wt and b-39 into pcDNA; pCI-neo-b+300+e3 was kindly
provided by Niels Gehring [48]. The following antibodies wereused in this study: mouse monoclonal anti-ROD1 (Santa Cruz cat.
No. sc-100845), goat polyclonal anti-UPF2 (Santa Cruz cat. No.
sc-20227), goat polyclonal anti-UPF1 (Bethyl cat. No. A300-036A)
and mouse monoclonal anti-ALY/REF (Millipore cat. No. 05-
1510). For control antibodies normal IgG derived from the corre-
sponding species were used.
4.2. Cell culture, transfections and RNAi
HEK293 cells were grown in DMEM supplemented with 10%
fetal calf serum; transfections were done with Lipofectamine
2000 according to manufacturer’s instructions; for the NMD as-
say, transfections were performed in 6-well plates with 0.8 lg
Fig. 5. A – ROD1 and UPF1 share a signiﬁcant proportion of RIP hits; areas are proportional to the number of transcripts. B – The RIP-seq and RIP-qPCR data sets correlate
signiﬁcantly; Paerson coefﬁcients and P values are indicated.
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pUC19 in combination with RNAi. RNAi was performed using
lentiviral particles (SIGMA–ALDRICH MISSION library) containing
shRNA driven by the U6 promotor (pLK0.1-shRNA); lentivirus
were produced by transfections in 293T cells according to stan-
dard protocols [49]; for transfection assays, transduction of cells
with lentivirus was done 48 h before transfection; cells were
harvested 24 h after transfection for RNA or protein extractions.
shRNA target sequences are as follows: ROD1: 50-GCCGTTACT
ATGGTGAATTAT-30; UPF1: 50-GCTGAGTTGAACTTCGAGGAA-30;
UPF2: 50-GCGAGATACGTCACAATGGTA-30; control: 50-ATTCTCCGA
ACGTGTCACG-30.
4.3. Protein extractions, immunoprecipitations and mass spectrometry
HEK293 cells were washed in cold PBS and protein extracts
were performed as described in [50], followed by dialysis in buffer
C-100 (20 mM HEPES pH 7.6, 0.2 mM EDTA, 1.5 mM MgCl2,
100 mM KCl, 20% glycerol). Extracts were centrifuged at 16000g
prior to immunoprecipitations to remove insoluble precipitates.
For immunoprecipitations, Dynabeads coupled with protein G
(Invitrogen) were washed several times with PBS and blocked with
200 lg/ml chicken egg albumin for 1 h at room temperature; 10 lg
control IgG or anti-ROD1 were then incubated with blocked beadsfor 30 min at R.T.; nuclear or cytoplasmic extracts were incubated
at 4 C with benzonase (150 l/ml) and protease inhibitors (Com-
plete, Roche). Extracts were incubated with beads and antibody
for 2 h at 4 C, beads were washed 5X with buffer C-100 + Com-
plete + 0.02% NP-40 and immunoprecipitated protein complexes
eluted in Laemli buffer at 99 C for 5 min. For Mass Spectrometry,
samples were loaded into a 10% SDS–PA gel followed by Colloidal
Blue Staining (Invitrogen); lanes were cut and submitted to in-
gel digestion with trypsin (Promega) as previously described
[51]. Nanoﬂow liquid chromatography-tandem mass spectrometry
was performed on a 1100 series capillary liquid chromatography
system (Agilent Technologies) coupled to an LTQ-orbitrap mass
spectrometer (Thermo) as previously described [52]. Matching
peptide fragmentation spectra to databases was performed with
Mascot as previously described [52]. Gene Ontology (GO) analysis
of ROD1 protein interactors was performed with Ingenuity Path-
way Analysis (core analysis).
4.4. Exon arrays
Total RNA from HEK293 cells targeted for knock-down of ROD1
or UPF1 was extracted with Trizol (Invitrogen) according to the
manufacturer’s instructions and puriﬁed using the Qiagen RNeasy
kit; RNA quality was assessed using the Agilent Bioanalyser. Fur-
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Affymetrix GeneChip WT Sense Target Labeling Assay. Affymetrix
GeneChip Human Exon 1.0 ST arrays were used to determine the
expression level of exons in the human genome (1.4 million probe
sets covering >1 million exon clusters). Data was analysed with
Partek Genomics Suite 6.4; background correction and normaliza-
tion of probe set intensities were done using the Robust Multi-ar-
ray Analysis and GC content was taken into account (GC-RMA)
[53]; probe set summarization was performed with median polish
settings. Exon-level data was ﬁltered to include only those probe
sets that are in the ‘‘core’’ meta-probe list. Differentially expressed
genes were detected using ANOVA (ANalysis Of VAriance); a cutoff
value of 1.5-fold was used to ﬁlter for up or down-regulated genes.
Up and down-regulated genes were classiﬁed according to molec-
ular function using the Ingenuity Pathway Analysis software. Chi-
squared tests were performed to assess statistical signiﬁcance in
overlapping gene groups. RT-PCR validations of up-regulated
genes, cycloheximide and DRB assays were done with duplicate
experiments; a threshold of 1.5-fold was set for conﬁrmation of
up-regulated targets.
4.5. RIP-seq
RNA immunoprecipitation was performed essentially as de-
scribed in [34]; lysis buffer II (10 mM HEPES pH 7.0, 100 mM KCl,
5 mM MgCl2, 25 mM EDTA, 0.5% Nonidet P-40, 1% Triton X-100,
0.1% sodium dodecyl sulfate, 10% glycerol) was used to prepare
HEK293 total extracts prior to immunoprecipitation. Sequencing
was performed in a GAIIx Illumina sequencer; the reads were
mapped to the hg19 genome sequence with the Bowtie alignment
tool ([54]) using a seed-length of 32 bases and a maximum number
of mismatches in the seed sequence of 2. In those cases in which
multiple alignments were possible, only the best alignment was re-
ported. These alignments were processed further using SeqMonk
version 0.16.0 (http://www.bioinformatics.bbsrc.ac.uk/projects/
seqmonk/) removing duplicate reads (RWWB: deﬁne duplicate).
Read counts per exon were exported and further data analysis
was done in R version 2.13.1 (http://www.r-project.org). Contrasts
with P-values of biological replicas between experimental and IgG
control exon read counts were calculated using edgeR version 2.2.5
(Robinson, 2011) after 58 non-unique exon names were removed.
P values were corrected for multiple testing by false discovery rate
(FDR) correction. For downstream analysis, one representative
exon was selected per gene based on lowest P-value. In case multi-
ple gene names mapped to the same exon, the shortest was se-
lected. Chi-squared tests were performed to assess statistical
signiﬁcance in overlapping gene groups.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.febslet.2012.03.
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